Landiolol is an ultra-short-acting, highly selective β1-adrenergic receptor blocker used for the rapid control of heart rate in patients with certain tachyarrhythmias. It is an active pharmaceutical ingredient used in pharmaceutical formulations for controlled cardiovascular applications.
Landiolol produces a rapid and titratable reduction in heart rate by selectively blocking β1-adrenergic receptors in cardiac tissue. Its very short duration of action allows its cardiovascular effects to be adjusted quickly following changes in administration.
Landiolol is a synthetic beta-adrenergic receptor antagonist belonging to the aryloxypropanolamine class. It has the molecular formula C25H39N3O8 and a molecular weight of approximately 509.60 g/mol. The CAS Number of Landiolol is 133242-30-5.
Landiolol is commonly supplied in pharmaceutical development and manufacturing as the hydrochloride salt, Landiolol Hydrochloride, depending on the product specification.
Landiolol selectively blocks β1-adrenergic receptors in the heart. This reduces the effects of catecholamines such as adrenaline and noradrenaline on cardiac tissue, resulting in decreased heart rate and reduced cardiac workload.
Its rapid onset and short elimination half-life make it suitable when short-term, closely controlled beta-blockade is required.
Landiolol is used in appropriate pharmaceutical formulations for the rapid control of ventricular rate in supraventricular tachyarrhythmias, including atrial fibrillation and atrial flutter, and for perioperative or acute-care heart-rate control where clinically indicated.
Landiolol API can be evaluated using validated analytical procedures for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
HPLC and suitable spectroscopic methods may be used for identity, assay and purity testing. Acceptance criteria should be based on the applicable pharmacopoeial monograph, regulatory specification or approved manufacturer's drug-substance specification and Certificate of Analysis.
Landiolol should be stored in a tightly closed pharmaceutical-grade container under controlled storage conditions. The material should be protected from excessive heat, moisture, direct light and contamination. Specific storage requirements should follow the applicable manufacturer's approved specification.
Landiolol API may be supplied for qualified pharmaceutical manufacturing, formulation development, research and analytical applications. Product specifications, Certificate of Analysis, packaging details and regulatory documentation should be confirmed according to the intended application.
Landiolol API is available for pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory requirements. Customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details for their specific requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |